D. Western Therapeutics Institute, Inc. (FRA:6DW)

Germany · Delayed Price · Currency is EUR

0.3300

-0.0040 (-1.20%)

Last updated: Jun 26, 2026, 8:08 AM CET

-49.23% (1Y)

Market Cap	21.51M -36.4%
Revenue (ttm)	1.66M -34.1%
Net Income	-3.56M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.3300
Previous Close	0.3340
Day's Range	0.3300 - 0.3300
52-Week Range	0.3160 - 0.8550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About FRA:6DW

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 19

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 6DW

Financial Performance

In 2025, FRA:6DW's revenue was 387.00 million, a decrease of -17.83% compared to the previous year's 471.00 million. Losses were -632.00 million, -51.01% less than in 2024.

Financial numbers in JPY Financial Statements